Stock Track | Burning Rock Biotech Soars 6.23% on Strong Q3 Results, Strategic Updates

Stock Track2024-12-04

Burning Rock Biotech Limited (BNR) saw its shares surge 6.23% in pre-market trading on Wednesday, following the release of its third quarter 2024 financial results.

The company reported revenue growth and margin expansion across its business segments. Total revenue increased 0.8% year-over-year to RMB128.6 million ($18.3 million), driven by a 17% increase in revenue from the in-hospital business and a 27.1% rise in pharma research and development services revenue.

Gross margins also improved significantly, with the company's overall gross margin rising to 71.4% from 67.4% a year ago. Non-GAAP gross margin reached 76%, compared to 74.5% in the prior-year period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment